Cocrystal PharmaCOCP.OValuation Analysis

As of Oct 16, 2026, Cocrystal Pharma (COCP.O) trades at a negative P/E (-1.98x, due to a recent net loss), P/B of 18.80x, P/S of N/A, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data); P/B sits at the 98th percentile over the trailing 10Y window (vs. 94th percentile over 3Y); P/S historical percentile is still accumulating data over the trailing long-term window (vs. the short-term percentile still accumulating data).
Cross-sectional valuation: its P/B ranks at the 95th percentile within its industry and the 96th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
Its P/B percentile is roughly the same whether measured against the industry or the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. Cocrystal Pharma operates in the Manufacturing sector. Data refreshes weekly and is for reference only, not investment advice.